Author:
Badrock Andrew P.,Hurlstone Adam
Reference21 articles.
1. Leonardi GC, Falzone L, Salemi R, Zanghi A, Spandidos DA, McCubrey JA, Candido S, Libra M (2018) Cutaneous melanoma: from pathogenesis to therapy (Review). Int J Oncol 52(4):1071–1080
2. Sanchez JN, Wang T, Cohen MS (2018) BRAF and MEK inhibitors: use and resistance in BRAF-mutated cancers. Drugs 78(5):549–566. https://doi.org/10.1007/s40265-018-0884-8
3. Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X (2019) Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer 18(1):26. https://doi.org/10.1186/s12943-019-0954-x
4. Kriplani N, Hermida MA, Brown ER, Leslie NR (2015) Class I PI 3-kinases: function and evolution. Adv Biol Regul 59:53–64. https://doi.org/10.1016/j.jbior.2015.05.002
5. Tatebe H, Shiozaki K (2017) Evolutionary conservation of the components in the TOR signaling pathways. Biomol Ther 7(4). https://doi.org/10.3390/biom7040077